🎈 Up Big Today: Find today's biggest gainers with our free screenerTry Stock Screener

Puma Biotech's patent suit sees mixed verdict

EditorNatashya Angelica
Published 16-09-2024, 08:24 pm
PBYI
-


LOS ANGELES, CA - Puma Biotechnology, Inc. (NASDAQ:PBYI) has experienced a series of legal developments in its patent infringement suit against AstraZeneca (NASDAQ:AZN), according to a recent SEC filing. The case, which involves claims that AstraZeneca's Tagrisso® infringes on two Puma patents, has seen a mixed verdict, with a jury ruling in favor of Puma's licensing partner Wyeth on infringement but the court later finding certain patent claims invalid.


The legal battle began on September 22, 2021, when Puma and co-plaintiff Wyeth filed suit against AstraZeneca alleging that the commercial activities surrounding Tagrisso®, a treatment for certain types of non-small cell lung cancer, infringed on U.S. Patent Nos. 10,603,314 and 10,596,162. Puma holds exclusive rights to these patents under an agreement with Pfizer (NYSE:PFE), Inc., the parent company of Wyeth.


Following a series of legal proceedings, including a Markman hearing and the closure of fact and expert discovery, the Court denied motions for summary judgment and Daubert motions from both parties. However, the Court clarified that damages could not be awarded for any period before the patents were issued. Puma was dismissed from the case on constitutional standing grounds, leaving Wyeth to continue the litigation.


In a jury trial held from May 13-17, 2024, Wyeth prevailed, with the jury finding that Tagrisso® infringed on the asserted patent claims and rejecting AstraZeneca's invalidity challenges. The jury awarded Wyeth damages amounting to $107.5 million for past infringement up to December 31, 2023.


Subsequently, a bench trial led to a ruling in favor of Wyeth on August 6, 2024, dismissing AstraZeneca's claims of patent invalidity and other defenses. However, the court partially granted AstraZeneca's motion for judgment as a matter of law on August 14, 2024, finding the patents invalid due to lack of enablement and adequate written description for a specific claim limitation. All other aspects of AstraZeneca's motion were denied.


Wyeth, maintaining its stance on the validity of the patents, filed a notice of appeal on September 12, 2024, challenging the court's judgment and other adverse rulings. The SEC filing stated that Puma maintains contractual rights to recover monetary damages from the AstraZeneca litigation, unaffected by the court's recent orders.


This complex legal matter continues to unfold, with both parties having completed briefing on post-trial motions as of July 16, 2024. The case is based on information disclosed in a press release statement.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.